Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

Core Insights - Arbutus Biopharma Corporation has made significant progress in its clinical research for chronic hepatitis B virus (cHBV), with multiple abstracts accepted for presentation at the AASLD – The Liver Meeting 2025, indicating advancements towards a potential functional cure for cHBV [1] Group 1: Imdusiran Clinical Data - Imdusiran (AB-729) has shown to be safe and well-tolerated in chronic hepatitis B patients, with a study reporting positive results from Phase 1 and 2 clinical trials [2] - A study suggests that imdusiran may enhance the responsiveness of pegylated interferon alfa-2a treatment in patients with specific HBV genotypes, particularly genotypes B and C [3] - Increases in soluble immune biomarkers were observed in subjects who lost HBsAg after treatment with imdusiran, indicating a potential immune response [4] Group 2: AB-101 Clinical Data - AB-101, an oral PD-L1 inhibitor, was well tolerated in chronic hepatitis B patients, with preliminary data showing significant receptor occupancy at higher doses [5][6] - The ongoing clinical trial for AB-101 is expected to provide further insights into its safety and pharmacodynamics [6] Group 3: Conference Details - The accepted abstracts will be publicly available on the AASLD website and published in the October supplement of HEPATOLOGY, with poster presentations accessible during the conference [7][8] Group 4: Company Overview - Arbutus Biopharma is focused on developing innovative therapies for infectious diseases, particularly cHBV, and is involved in legal actions to protect its intellectual property related to its patented LNP technology [12]